aran biomedical Archives - Medical Design Sourcing

Integer grows sales 12% in Q2, driven by recent acquisitions

Integer (NYSE:ITGR) posted second-quarter results today that beat the overall consensus forecast on Wall Street.

The Plano, Texas-based medical device outsource manufacturer reported profits of $20.8 million, or 62¢ per share, on sales of $350 million for the three months ended July 1, for a bottom-line loss of 29.2% on sales growth of 12.2% compared with Q2 2021.

Adjusted to exclude one-time items, earnings per share were $1.04, 8¢ ahead of The Street, where analysts were looking for sales of $43.57 million.

“Integer delivered second quarter 2022 financial results consistent with our expectations, as sales grew 13% versus the first quarter 2022 and 12% versus prior year. Integer’s associates around the globe remain focused on delivering products for our customers and the patients they serve, while managing the challenges of the ongoing labor and supply chain dynamics,” President and CEO Joseph Dziedzic said in a news release.

Cardio and vascular …

Integer buys Aran Biomedical for $131.1 million

Integer (NYSE:ITGR) announced today that it acquired Connemara Biomedical and its subsidiaries Aran Biomedical and Proxy Biomedical (collectively “Aran”).

Aran offers development and manufacturing solutions for implantable medical devices, including proprietary medical textiles, high-precision biomaterial coverings and coatings along with advanced metal and polymer braiding.

Get the full story at our sister site, Medical Design & Outsourcing.

Integer buys Aran Biomedical for $131.1 million

Integer (NYSE:ITGR) announced today that it acquired Connemara Biomedical and its subsidiaries Aran Biomedical and Proxy Biomedical (collectively “Aran”).

Aran offers development and manufacturing solutions for implantable medical devices, including proprietary medical textiles, high-precision biomaterial coverings and coatings along with advanced metal and polymer braiding.

The deal to acquire Aran Biomedical is worth $131.1 million (€120 million) with up to an additional $10.9 million (€10 million) in contingent consideration based on 2022 revenue growth milestones.

Plano, Texas-based Integer said in a news release that Galway, Ireland-based Aran further increases its ability to offer complete solutions for complex delivery and therapeutic devices in high-growth cardiovascular markets, including structural heart, neurovascular, peripheral vascular and endovascular, as well as in general surgery.

Integer said Aran’s Ireland head…